...
govx-img

GeoVax Labs Inc, Common Stock

GOVX

NAQ

$2.255

+$0.04

(1.81%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.85M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
345.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.11
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.09 L
$11.18 H
$2.255

About GeoVax Labs Inc, Common Stock

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGOVXSectorS&P500
1-Week Return-3.49%-0.4%-1.9%
1-Month Return-26.58%-4.57%-0.37%
3-Month Return-19.05%-10.14%4.19%
6-Month Return-27.06%-5.67%9.34%
1-Year Return-59.63%2.53%25.19%
3-Year Return-96.33%-0.39%26.48%
5-Year Return-99.08%34.57%85.39%
10-Year Return-100%103.62%187.16%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.18M1.82M385.00K81.00K-[{"date":"2019-12-31","value":64.5,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":21.12,"profit":true},{"date":"2022-12-31","value":4.44,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue1.91M2.44M15.55M56.28K20.72M[{"date":"2019-12-31","value":9.22,"profit":true},{"date":"2020-12-31","value":11.8,"profit":true},{"date":"2021-12-31","value":75.07,"profit":true},{"date":"2022-12-31","value":0.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(734.82K)1.82M385.00K81.00K(20.72M)[{"date":"2019-12-31","value":-40.31,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":21.12,"profit":true},{"date":"2022-12-31","value":4.44,"profit":true},{"date":"2023-12-31","value":-1136.63,"profit":false}]
Gross Margin(62.49%)100.00%100.00%100.00%-[{"date":"2019-12-31","value":-62.49,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses3.55M4.64M19.13M14.11M6.02M[{"date":"2019-12-31","value":18.55,"profit":true},{"date":"2020-12-31","value":24.25,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.75,"profit":true},{"date":"2023-12-31","value":31.48,"profit":true}]
Operating Income(2.37M)(2.82M)(18.75M)(14.03M)(26.74M)[{"date":"2019-12-31","value":-237249300,"profit":false},{"date":"2020-12-31","value":-281700000,"profit":false},{"date":"2021-12-31","value":-1874600000,"profit":false},{"date":"2022-12-31","value":-1402900000,"profit":false},{"date":"2023-12-31","value":-2674293900,"profit":false}]
Total Non-Operating Income/Expense3.73K(282.25K)179.45K14.44K1.45M[{"date":"2019-12-31","value":0.26,"profit":true},{"date":"2020-12-31","value":-19.4,"profit":false},{"date":"2021-12-31","value":12.34,"profit":true},{"date":"2022-12-31","value":0.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(2.37M)(2.96M)(18.57M)(14.02M)(25.97M)[{"date":"2019-12-31","value":-237062900,"profit":false},{"date":"2020-12-31","value":-295800000,"profit":false},{"date":"2021-12-31","value":-1857000000,"profit":false},{"date":"2022-12-31","value":-1402200000,"profit":false},{"date":"2023-12-31","value":-2596676200,"profit":false}]
Income Taxes4.50K(19.66K)(38.52K)(7.44K)1.00[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-437.29,"profit":false},{"date":"2021-12-31","value":-856.97,"profit":false},{"date":"2022-12-31","value":-165.49,"profit":false},{"date":"2023-12-31","value":0.02,"profit":true}]
Income After Taxes(2.38M)(2.94M)(18.53M)(14.01M)(25.97M)[{"date":"2019-12-31","value":-237512400,"profit":false},{"date":"2020-12-31","value":-293834400,"profit":false},{"date":"2021-12-31","value":-1853147900,"profit":false},{"date":"2022-12-31","value":-1401456100,"profit":false},{"date":"2023-12-31","value":-2596676300,"profit":false}]
Income From Continuous Operations(2.37M)(2.96M)(18.57M)(14.02M)(23.76M)[{"date":"2019-12-31","value":-237062900,"profit":false},{"date":"2020-12-31","value":-295806800,"profit":false},{"date":"2021-12-31","value":-1857000000,"profit":false},{"date":"2022-12-31","value":-1402112500,"profit":false},{"date":"2023-12-31","value":-2375816300,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(2.38M)(2.94M)(18.53M)(14.01M)(25.97M)[{"date":"2019-12-31","value":-237512400,"profit":false},{"date":"2020-12-31","value":-293834400,"profit":false},{"date":"2021-12-31","value":-1853147900,"profit":false},{"date":"2022-12-31","value":-1401456100,"profit":false},{"date":"2023-12-31","value":-2596676200,"profit":false}]
EPS (Diluted)(98.80K)(2.04)(3.04)(0.89)(14.29)[{"date":"2019-12-31","value":-9880252,"profit":false},{"date":"2020-12-31","value":-204,"profit":false},{"date":"2021-12-31","value":-304,"profit":false},{"date":"2022-12-31","value":-89,"profit":false},{"date":"2023-12-31","value":-1429,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GOVX
Cash Ratio 3.29
Current Ratio 4.17

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GOVX
ROA (LTM) -134.35%
ROE (LTM) -362.39%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GOVX
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GOVX
Trailing PE NM
Forward PE 10.63
P/S (TTM) 69.36
P/B 2.45
Price/FCF NM
EV/R 6.29
EV/Ebitda 0.10
PEG NM

FAQs

What is GeoVax Labs Inc share price today?

GeoVax Labs Inc (GOVX) share price today is $2.255

Can Indians buy GeoVax Labs Inc shares?

Yes, Indians can buy shares of GeoVax Labs Inc (GOVX) on Vested. To buy GeoVax Labs Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GOVX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of GeoVax Labs Inc be purchased?

Yes, you can purchase fractional shares of GeoVax Labs Inc (GOVX) via the Vested app. You can start investing in GeoVax Labs Inc (GOVX) with a minimum investment of $1.

How to invest in GeoVax Labs Inc shares from India?

You can invest in shares of GeoVax Labs Inc (GOVX) via Vested in three simple steps:

  • Click on Sign Up or Invest in GOVX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in GeoVax Labs Inc shares
What is GeoVax Labs Inc 52-week high and low stock price?

The 52-week high price of GeoVax Labs Inc (GOVX) is $11.18. The 52-week low price of GeoVax Labs Inc (GOVX) is $1.09.

What is GeoVax Labs Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of GeoVax Labs Inc (GOVX) is

What is GeoVax Labs Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of GeoVax Labs Inc (GOVX) is 2.45

What is GeoVax Labs Inc dividend yield?

The dividend yield of GeoVax Labs Inc (GOVX) is 0.00%

What is the Market Cap of GeoVax Labs Inc?

The market capitalization of GeoVax Labs Inc (GOVX) is $20.85M

What is GeoVax Labs Inc’s stock symbol?

The stock symbol (or ticker) of GeoVax Labs Inc is GOVX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top